Microparticles and nanoparticles as delivery systems for DNA vaccines.
about
Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental designBiodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model.Tresyl-based conjugation of protein antigen to lipid nanoparticles increases antigen immunogenicity.Harmine: evaluation of its antileishmanial properties in various vesicular delivery systems.Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen.Protective effect of recombinant staphylococcal enterotoxin A entrapped in polylactic-co-glycolic acid microspheres against Staphylococcus aureus infection.Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy.Protein adsorption and cellular uptake of cerium oxide nanoparticles as a function of zeta potential.Recent advances in delivery systems for anti-HIV1 therapy.Nanoparticles in modern medicine: state of the art and future challenges.Nanoparticles and microparticles as vaccine-delivery systems.Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccinesAg85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune ResponsesProtonated nanoparticle surface governing ligand tethering and cellular targeting.Strong antibody responses induced by protein antigens conjugated onto the surface of lecithin-based nanoparticlesLiposomes as drug delivery systems for the treatment of TB.Mannan-mediated gene delivery for cancer immunotherapy.Evaluation of different chemical adjuvants on an avian influenza H6 DNA vaccine in chickens.Alginate nanoparticles as a promising adjuvant and vaccine delivery system.Critical evaluation of the therapeutic potential of bassic acid incorporated in oil-in-water microemulsions and poly-D,L-lactide nanoparticles against experimental leishmaniasis.Characterization of particles fabricated with poly(D, L-lactic-co-glycolic acid) and an ornithine-histidine peptide as carriers of oligodeoxynucleotide for delivery into primary dendritic cells.Immunotherapy for Alzheimer's disease
P2860
Q33779670-3EFE2666-9E11-4956-A696-365CCF72F505Q34063125-EE78DA5D-F81E-4F2F-923B-BA28B5CDBEACQ34258873-45A59E8C-FF44-420C-B8DB-45AB9E91C0CAQ34327597-F7825043-BCC3-4B99-8A47-48F9AFACA0E9Q35192726-F18EB357-8EC7-45E4-B4B0-FD5379329FB2Q35963399-DB63BB29-9494-446A-9CF5-AEAAE8F9E1FBQ36299906-5791E3E5-EEDB-4AEC-984B-FD2ECDABF926Q36485131-D6F94B23-F992-49B0-A72B-C3AC2ADDD8A5Q36761854-EAA3A421-252F-4810-A00F-0578FA8EFB8AQ36920457-459194AB-265F-4BA3-AFF9-759E01C7BD7BQ36968297-B21F6118-8319-4972-879E-78BEB190AAEBQ37156758-823A7258-C1ED-4ED6-8688-E8F69A86E0BEQ37293872-854CBB7F-4786-47C6-8734-D16D5FA6E6A3Q37395853-E6E02778-4DFC-4C8F-917C-FAB928F80B8CQ37463831-CE4C81FF-93F7-4996-8348-6DCC4D6084D9Q37949386-4B94CEE7-4722-41B6-AAA9-7C31FA5B6715Q40165469-8D29D525-8B67-4783-B812-B96092A37D39Q40499124-30B50788-8FC8-4B9A-A1C4-68BE24E40C1BQ42238199-A5BDA3B1-7615-48E9-9B9B-61B0DFB01C80Q51806767-9CD54691-F5CA-46C5-AA0B-332768907C97Q53574381-0625C46B-E3DE-4044-A581-842B99DD7660Q57419087-92E21F97-7CA2-43F1-A9CA-78808A3D1AE7
P2860
Microparticles and nanoparticles as delivery systems for DNA vaccines.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@ast
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@en
type
label
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@ast
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@en
prefLabel
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@ast
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@en
P1476
Microparticles and nanoparticles as delivery systems for DNA vaccines.
@en
P2093
Russell J Mumper
Zhengrong Cui
P304
P356
10.1615/CRITREVTHERDRUGCARRIERSYST.V20.I23.10
P577
2003-01-01T00:00:00Z